JP2020535151A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020535151A5 JP2020535151A5 JP2020517143A JP2020517143A JP2020535151A5 JP 2020535151 A5 JP2020535151 A5 JP 2020535151A5 JP 2020517143 A JP2020517143 A JP 2020517143A JP 2020517143 A JP2020517143 A JP 2020517143A JP 2020535151 A5 JP2020535151 A5 JP 2020535151A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- seq
- antibody
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 37
- 239000012634 fragment Substances 0.000 claims 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 13
- 201000010099 disease Diseases 0.000 claims 12
- 208000024891 symptom Diseases 0.000 claims 7
- 239000000825 pharmaceutical preparation Substances 0.000 claims 6
- 230000002265 prevention Effects 0.000 claims 5
- 108010074051 C-Reactive Protein Proteins 0.000 claims 4
- 102100032752 C-reactive protein Human genes 0.000 claims 4
- 208000008035 Back Pain Diseases 0.000 claims 2
- 206010019233 Headaches Diseases 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 208000000112 Myalgia Diseases 0.000 claims 2
- 206010028813 Nausea Diseases 0.000 claims 2
- 206010044565 Tremor Diseases 0.000 claims 2
- 206010047700 Vomiting Diseases 0.000 claims 2
- 230000004872 arterial blood pressure Effects 0.000 claims 2
- 231100000869 headache Toxicity 0.000 claims 2
- 230000008693 nausea Effects 0.000 claims 2
- 229940127557 pharmaceutical product Drugs 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 230000008673 vomiting Effects 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000014644 Brain disease Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 102000016550 Complement Factor H Human genes 0.000 claims 1
- 108010053085 Complement Factor H Proteins 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 230000004071 biological effect Effects 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000010412 perfusion Effects 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17192999 | 2017-09-25 | ||
| EP17192999.5 | 2017-09-25 | ||
| EP17203370.6 | 2017-11-23 | ||
| EP17203370 | 2017-11-23 | ||
| PCT/EP2018/075987 WO2019057992A2 (en) | 2017-09-25 | 2018-09-25 | ANTI-ADRENOMEDULIN (ADM) BINDER FOR USE IN TREATING OR PREVENTING THE SYMPTOMS OF A DISEASE |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2020535151A JP2020535151A (ja) | 2020-12-03 |
| JP2020535151A5 true JP2020535151A5 (enExample) | 2021-11-04 |
| JPWO2019057992A5 JPWO2019057992A5 (enExample) | 2022-03-24 |
| JP7461875B2 JP7461875B2 (ja) | 2024-04-04 |
Family
ID=63722372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020517143A Active JP7461875B2 (ja) | 2017-09-25 | 2018-09-25 | 病気の症状の治療又は予防に使用するための抗アドレノメデュリン（ａｄｍ）バインダー |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20220227854A1 (enExample) |
| EP (5) | EP4488295A3 (enExample) |
| JP (1) | JP7461875B2 (enExample) |
| KR (2) | KR20250004928A (enExample) |
| CN (2) | CN119215164A (enExample) |
| AU (2) | AU2018335438B2 (enExample) |
| BR (1) | BR112020005450A2 (enExample) |
| CA (1) | CA3076691A1 (enExample) |
| DK (1) | DK3687567T3 (enExample) |
| ES (1) | ES3001197T3 (enExample) |
| FI (1) | FI3687567T3 (enExample) |
| HR (1) | HRP20241795T1 (enExample) |
| HU (1) | HUE069945T2 (enExample) |
| IL (1) | IL273533A (enExample) |
| LT (1) | LT3687567T (enExample) |
| MX (1) | MX2020003538A (enExample) |
| MY (1) | MY204700A (enExample) |
| PL (1) | PL3687567T3 (enExample) |
| RS (1) | RS66415B1 (enExample) |
| SG (1) | SG11202002258WA (enExample) |
| SI (1) | SI3687567T1 (enExample) |
| WO (1) | WO2019057992A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3148275A1 (en) | 2019-08-30 | 2021-03-04 | 4TEEN4 Pharmaceuticals GmbH | Therapy guidance and/or therapy monitoring for treatment of shock |
| EP3871689A1 (en) * | 2020-02-26 | 2021-09-01 | sphingotec GmbH | Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c |
| MX2022010207A (es) * | 2020-02-27 | 2022-11-16 | Adrenomed Ag | Anticuerpo anti-adrenomedulina (adm) o fragmento de anticuerpo anti-adm o andamiaje no ig anti-adm para usarse en terapia o prevencion de choque. |
| BR112022017890A2 (pt) * | 2020-03-16 | 2022-11-01 | Sphingotec Gmbh | Proadrenomedulina ou fragmento da mesma em pacientes infectados com coronavírus e tratamentos com ligante contra adrenomedulina |
| CN111893085A (zh) * | 2020-08-04 | 2020-11-06 | 北京臻溪谷医学研究中心（有限合伙） | 一种通过干细胞体外分化获得人工皮肤的方法及其应用 |
| WO2024017331A1 (zh) * | 2022-07-20 | 2024-01-25 | 上海济煜医药科技有限公司 | 一种抗肾上腺髓质素非中和抗体、其制备方法及应用 |
| WO2025152915A1 (zh) * | 2024-01-16 | 2025-07-24 | 上海济煜医药科技有限公司 | 抗肾上腺髓质素抗体在预防或治疗脑卒中的应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| JP2005508623A (ja) | 2001-08-30 | 2005-04-07 | バイオレクシス ファーマシューティカル コーポレイション | 改変されたトランスフェリン融合タンパク質 |
| ATE528014T1 (de) | 2002-06-07 | 2011-10-15 | Dyax Corp | Polypeptid mit modifizierten kunitz domains |
| AU2004284090A1 (en) | 2003-10-24 | 2005-05-06 | Avidia, Inc. | LDL receptor class A and EGF domain monomers and multimers |
| US20100028995A1 (en) | 2004-02-23 | 2010-02-04 | Anaphore, Inc. | Tetranectin Trimerizing Polypeptides |
| EP1793847A2 (en) | 2004-09-21 | 2007-06-13 | NascaCell IP GmbH | Use of microproteins as tryptase inhibitors |
| ES2373832T3 (es) | 2007-12-19 | 2012-02-09 | Affibody Ab | Polipéptido derivado de proteína a y capaz de unirse a pdgf. |
| RU2550258C2 (ru) | 2008-11-03 | 2015-05-10 | Молекьюлар Партнерс Аг | Связывающие белки, ингибирующие взаимодействия vegf-a рецептора |
| CA2772162C (en) | 2009-08-27 | 2018-05-22 | Covagen Ag | Anti-il-17a fynomers and medical uses thereof |
| SI2506871T1 (sl) * | 2009-11-30 | 2016-12-30 | Janssen Biotech, Inc. | Mutanti Fc protitelesa z odstranjenimi efektorskimi funkcijami |
| BR112012014194A2 (pt) | 2009-12-14 | 2017-01-10 | Scil Proteins Gmbh | um método para identificar proteínas ubiquitinas modificadas hetero-multiméricas com capacidade de ligação a ligandos |
| SMT201900297T1 (it) | 2010-06-08 | 2019-07-11 | Astrazeneca Ab | Muteine di lipocalina lacrimale che si legano a il-4 r alfa |
| PL2780370T3 (pl) | 2011-11-16 | 2020-01-31 | Adrenomed Ag | Przeciwciało przeciwko adrenomedulinie (adm) lub fragment przeciwciała przeciwko adp lub szkielet przeciwko adm inny niż ig do zastosowania do stabilizacji krążenia w terapii ostrej choroby lub ostrego stanu pacjenta |
| ES2729710T3 (es) * | 2011-11-16 | 2019-11-05 | Adrenomed Ag | Anticuerpo antiadrenomedulina (ADM) o fragmento de anticuerpo anti-ADM o andamiaje no Ig anti-ADM para la prevención o la reducción de una disfunción orgánica o una insuficiencia orgánica en un paciente que presenta una enfermedad crónica o aguda o una afección aguda |
| PL2594587T3 (pl) * | 2011-11-16 | 2014-11-28 | Adrenomed Ag | Przeciwciało przeciwko adrenomedulinie (ADM) lub fragment przeciwciała anty-ADM lub szkielet białkowy niestanowiący Ig anty-ADM do zmniejszenia ryzyka śmierci u pacjenta cierpiącego na chorobę przewlekłą lub ostrą lub stan ostry |
| JP6321545B2 (ja) * | 2011-11-16 | 2018-05-09 | アドレノメト アクチェンゲゼルシャフト | 治療法における使用のための抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場 |
| RS55804B1 (sr) * | 2011-11-16 | 2017-08-31 | Sphingotec Gmbh | Testovi za adrenomedulin i metodi za određivanje zrelog adrenomedulina |
| EP2976646B1 (en) * | 2013-03-20 | 2020-08-19 | sphingotec GmbH | Adrenomedullin to guide therapy of blood pressure decline |
| WO2017186928A1 (en) * | 2016-04-29 | 2017-11-02 | Curevac Ag | Rna encoding an antibody |
| US20200299372A1 (en) * | 2016-12-16 | 2020-09-24 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof |
-
2018
- 2018-09-25 CN CN202411206189.XA patent/CN119215164A/zh active Pending
- 2018-09-25 EP EP24205659.6A patent/EP4488295A3/en active Pending
- 2018-09-25 RS RS20241461A patent/RS66415B1/sr unknown
- 2018-09-25 BR BR112020005450-0A patent/BR112020005450A2/pt unknown
- 2018-09-25 JP JP2020517143A patent/JP7461875B2/ja active Active
- 2018-09-25 EP EP22198106.1A patent/EP4159229A1/en active Pending
- 2018-09-25 AU AU2018335438A patent/AU2018335438B2/en active Active
- 2018-09-25 HU HUE18781997A patent/HUE069945T2/hu unknown
- 2018-09-25 EP EP22198142.6A patent/EP4159230A1/en active Pending
- 2018-09-25 MY MYPI2020001569A patent/MY204700A/en unknown
- 2018-09-25 DK DK18781997.4T patent/DK3687567T3/da active
- 2018-09-25 LT LTEPPCT/EP2018/075987T patent/LT3687567T/lt unknown
- 2018-09-25 CA CA3076691A patent/CA3076691A1/en active Pending
- 2018-09-25 FI FIEP18781997.4T patent/FI3687567T3/fi active
- 2018-09-25 WO PCT/EP2018/075987 patent/WO2019057992A2/en not_active Ceased
- 2018-09-25 ES ES18781997T patent/ES3001197T3/es active Active
- 2018-09-25 CN CN201880062062.1A patent/CN111511390B/zh active Active
- 2018-09-25 SI SI201831189T patent/SI3687567T1/sl unknown
- 2018-09-25 SG SG11202002258WA patent/SG11202002258WA/en unknown
- 2018-09-25 EP EP21154857.3A patent/EP3854414A1/en not_active Withdrawn
- 2018-09-25 PL PL18781997.4T patent/PL3687567T3/pl unknown
- 2018-09-25 US US16/650,474 patent/US20220227854A1/en active Pending
- 2018-09-25 KR KR1020247040657A patent/KR20250004928A/ko active Pending
- 2018-09-25 HR HRP20241795TT patent/HRP20241795T1/hr unknown
- 2018-09-25 KR KR1020207011620A patent/KR20200088302A/ko not_active Ceased
- 2018-09-25 EP EP18781997.4A patent/EP3687567B1/en active Active
- 2018-09-25 MX MX2020003538A patent/MX2020003538A/es unknown
-
2020
- 2020-03-23 IL IL273533A patent/IL273533A/en unknown
-
2023
- 2023-03-09 AU AU2023201479A patent/AU2023201479A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020535151A5 (enExample) | ||
| Sinitski et al. | Macrophage migration inhibitory factor (MIF)-based therapeutic concepts in atherosclerosis and inflammation | |
| JP7725551B2 (ja) | アクチビンｉｉａ型受容体変異体を含む医薬組成物 | |
| JP7101621B2 (ja) | 単一ドメイン血清アルブミン結合タンパク質 | |
| KR102835308B1 (ko) | Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질 | |
| KR102249078B1 (ko) | 요법에 사용하기 위한 항-아드레노메둘린 (adm) 항체 또는 항-adm 항체 단편 또는 항-adm 비-ig 스캐폴드 | |
| JP2008508882A5 (enExample) | ||
| JP6193871B2 (ja) | 慢性若しくは急性疾患又は急性病態に罹患している患者の臓器機能障害又は臓器不全を予防又は軽減するための、抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場 | |
| JP6224608B2 (ja) | 血液循環を安定化させるための、患者の急性疾患又は急性病態の治療法における使用に向けた、抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場 | |
| JP6105146B2 (ja) | Ｐａｎ−ＥＬＲ＋ＣＸＣケモカイン抗体 | |
| CN111344306A (zh) | 结合alk-1和bmpr-2的双特异性抗体 | |
| TW201116624A (en) | Dual variable domain immunoglobulin and uses thereof | |
| JP2022532812A (ja) | 抗ｉｌ１ｒａｐ抗体組成物 | |
| CN111511390B (zh) | 用于治疗或预防疾病症状的抗肾上腺髓质素(adm)结合剂 | |
| WO2013072510A1 (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition | |
| JP2023052614A (ja) | うっ血の処置と治療を必要とする患者でその処置と治療に使用するための抗アドレノメデュリン（ＡＤＭ）抗体、または抗ＡＤＭ抗体フラグメント、または抗ＡＤＭ非Ｉｇ足場 | |
| JPWO2019057992A5 (enExample) | ||
| CN116199795B (zh) | 融合蛋白及其用途 | |
| CN108431039B (zh) | 改进的p2x7受体结合剂和包含其的多肽 | |
| Ando et al. | Creation of mouse TNFR2-selective agonistic TNF mutants using a phage display technique | |
| JPWO2019193029A5 (enExample) | ||
| Wang et al. | A study on inhibition of inflammation via p75TNFR signaling pathway activation in mice with traumatic brain injury | |
| EP4345109A1 (en) | Anti-adrenomedullin (adm) binder for use in therapy of pediatric patients with congenital heart disease | |
| RU2790561C2 (ru) | Соединение, связывающее адреномедуллин (adm), для применения для терапии или профилактики симптомов заболевания | |
| RU2022112502A (ru) | Соединение, связывающее адреномедуллин (adm), для применения для терапии или профилактики симптомов заболевания |